Exploring the efficacy of repeated low-level red-light therapy in retarding childhood myopia progression: updated systematic review and meta-analysis.

Abstract

<h4>Background</h4>Due to the increasing prevalence of childhood myopia, low-level red-light therapy has surfaced as a non-pharmacological method to mitigate its advancement. This systematic review and meta-analysis evaluates the efficacy of repeated low-level red-light (RLRL) in pediatric populations, providing evidence-based support for its therapeutic usage.<h4>Methods</h4>A search was performed in PubMed, Web of Science, Cochrane Library, Embase, and prominent Chinese databases, including CNKI, VIP, and Wanfang, from their inception until May 13, 2025. This meta-analysis includes randomized controlled trials (RCTs) that matched the inclusion criteria and was analyzed using Stata software, version 18.0.<h4>Results</h4>This meta-analysis included 1,053 participants: 515 in the RLRL and 538 in the control groups. The SMD for SER reduction was 0.84 (95% CI: 0.50, 1.19), SMD for AL reduction was -1.01, (95% CI: -1.60, -0.41), and SMD for SFChT rise was 0.81 (95% CI: 0.65-0.98). There is no major publishing bias.<h4>Conclusion</h4>The meta-analysis found that children with myopia who got RLRL therapy in addition to normal treatment had significantly slower disease progression than the control group.<h4>Systematic review registration</h4>https://www.crd.york.ac.uk/PROSPERO/view/CRD420251034037, PROSPERO 2025 CRD420251034037.